Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2022-03-31 Director's Dealing
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
Director's Dealing 2022
Director's Dealing
2022-03-31 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 9, 2022. It reports an amendment to the company's bylaws regarding the removal of cumulative voting for directors. The content focuses on a corporate governance change rather than financial results or detailed management discussion. The document length is 3041 characters, which is relatively short and contains a specific announcement about board governance changes. This fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. It is not an annual or quarterly report, audit report, or earnings release. It is not a proxy statement or voting results announcement. Therefore, the classification is MANG with high confidence.
2022-03-09 English
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce major events or material definitive agreements by a company. The text describes the entry into a material definitive agreement and amendments related to a collaborative agreement with BioLite, including payment terms and related party transactions. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. It is not a transcript, proxy, or governance document. The document is a regulatory announcement of a material event, fitting the category of a Regulatory Filing (RNS). The document length is 5849 characters, which is consistent with a detailed 8-K filing but not a full financial report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-02-22 English
Director's Dealing 2021
Director's Dealing
2021-12-10 English
Director's Dealing 2021
Director's Dealing
2021-12-10 English
Regulatory Filings 2021
Regulatory Filings
2021-11-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.